LYNPARZA (OLAPARIB) ACCEPTED FOR USE IN SCOTLAND TO TREAT GERMLINE BRCA-MUTATED HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER CHEMOTHERAPY

Contributed by: AstraZeneca

Tags

Breast cancer Scotland
Scotland health

More Like This

Dr Stuart Griffiths, Director of Research, Policy and Impact at Yorkshire Cancer Research.

People with genetic cancer risk to help shape future of prevention in bold new study

PR Newswire associated0

European Organisation for Research and Treatment of Cancer & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer

ASTRAZENECA RECEIVES TWO POSITIVE NICE RECOMMENDATIONS FOR LUNG CANCER PATIENTS ACROSS ENGLAND AND WALES

PR Newswire associated0

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

PATIENTS IN SCOTLAND GAIN ACCESS TO CANCER TREATMENTS FOR LUNG CANCER AND CHRONIC LYMPHOCYTIC LEUKAEMIA FOLLOWING SMC DECISIONS

PR Newswire associated0

European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

PR Newswire associated0

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

PR Newswire associated0

Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium